<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2521-2281</journal-id>
<journal-title><![CDATA[Medicina clínica y social]]></journal-title>
<abbrev-journal-title><![CDATA[Med. clín. soc.]]></abbrev-journal-title>
<issn>2521-2281</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Ciencias Médicas, Filial de Santa Rosa del Aguaray, Cátedra de Socioantropología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2521-22812025000100223</article-id>
<article-id pub-id-type="doi">10.52379/mcs.v9.577</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Características clínicas y autoanticuerpos en pacientes con Lupus Eritematoso Sistémico que acuden al Hospital Nacional. Periodo 2018 -2023]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical characteristics and frequency of autoantibodies in patients with Systemic Lupus Erythematosus who attend the National Hospital in the period 2018 -2023]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[Luis Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montiel Jarolin]]></surname>
<given-names><![CDATA[Dora]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jarolin Montiel]]></surname>
<given-names><![CDATA[Magali]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Samudio]]></surname>
<given-names><![CDATA[Margarita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Itapúa  ]]></institution>
<addr-line><![CDATA[Encarnación ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Nacional Centro Médico Nacional Departamento de Medicina Interna]]></institution>
<addr-line><![CDATA[Itauguá ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad del Pacífico Dirección de Investigación ]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>9</volume>
<numero>1</numero>
<fpage>223</fpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2521-22812025000100223&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2521-22812025000100223&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2521-22812025000100223&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  El lupus eritematoso sistémico (LES) es una enfermedad autoinmune caracterizada por disfunción inmunológica y síntomas multisistémicos, incluyendo manifestaciones renales, dermatológicas, neuropsiquiátricas y cardiovasculares. Los biomarcadores son clave en el diagnóstico, evaluación y control de la enfermedad.  Objetivo:  Determinar las características clínicas y autoanticuerpos en pacientes con LES hospitalizados en el Hospital Nacional entre 2018 a octubre de 2023.  Metodología:  Estudio observacional descriptivo transversal con asociación cruzada que incluyó pacientes con LES. Se analizaron características demográficas, clínicas, y la presencia de los anticuerpos (anti DNA, anti-Sm, anti-RNP, anti-Ro, anti-La, anti-jo, factor reumatoide (FR), anti-p ribosomal, anti-histona, anticardiolipina y anticoagulante lúpico. Se utilizó estadística descriptiva y prueba de chi cuadrado con un nivel de significancia de 0,05.  Resultados:  Se incluyeron 164 pacientes (87% mujeres) con una edad mediana de 29,6 y rango intercuartílico de 20 años. El 51,8% presentaba actividad severa de la enfermedad; las principales manifestaciones clínicas fueron alopecia (81,7%), artralgias (75,6%), cefalea (67,7%), eritema malar (58,5%), artritis (34,8%), en igual proporción (31,7%) nefritis y fiebre prolongada. Los principales autoanticuerpos fueron el anti DNA (60%), anti Ro (44%), anti Sm (32%) y FR (24%). Se observaron niveles bajos de C3 en 59% y C4 en 51,2%. Los autoanticuerpos anti DNA, anti rnp y anti-pribosomal se asociaron con nefritis; y el anti Sm con síndrome de Raynaud.  Conclusión:  Alopecia y artralgias fueron las manifestaciones más frecuentes. Anti-DNA, anti-Ro y anti-Sm destacaron como biomarcadores clave, con asociaciones relevantes que refuerzan su utilidad en el manejo del LES.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune system dysfunction and multisystem involvement, including renal, dermatologic, neuropsychiatric, and cardiovascular manifestations. Biomarkers play a key role in diagnosis, assessment, and disease management.  Objective:  To determine the clinical characteristics and autoantibodies in patients with SLE hospitalized at the National Hospital between 2018 and October 2023.  Methodology:  A cross-sectional, observational descriptive study with cross-association was conducted, including SLE patients hospitalized at the National Hospital. Demographic and clinical characteristics, along with the presence of autoantibodies (anti-DNA, anti-Sm, anti-RNP, anti-Ro, anti-La, anti-Jo, rheumatoid factor [RF], anti-p ribosomal, anti-histone, anticardiolipin, and lupus anticoagulant), were analyzed. Descriptive statistics and chi-square test were used, with a significance level of 0.05.  Results:  A total of 164 patients were included (87% female), with a median age of 29.6 years. Disease activity was severe in 51.8% of cases. The most common clinical manifestations were alopecia (81.7%), arthralgia (75.6%), headache (67.7%), malar rash (58.5%), arthritis (34.8%), nephritis and prolonged fever (31.7%). The most frequent autoantibodies were anti-DNA (60%), anti-Ro (44%), anti-Sm (32%), and RF (24%). Low levels of C3 and C4 were found in 59% and 51.2% of patients, respectively. Anti-DNA, anti-RNP, and anti-p ribosomal antibodies were associated with nephritis; anti-Sm with Raynaud&#8217;s syndrome.  Conclusion:  Alopecia and arthralgia were the predominant clinical features. Anti-DNA, anti-Ro, and anti-Sm were the most frequent autoantibodies, with significant associations that underscore their importance in SLE management.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Lupus eritematoso sistémico]]></kwd>
<kwd lng="es"><![CDATA[auto anticuerpos]]></kwd>
<kwd lng="es"><![CDATA[signos y síntomas]]></kwd>
<kwd lng="es"><![CDATA[pruebas serológicas]]></kwd>
<kwd lng="en"><![CDATA[Systemic lupus erythematosus]]></kwd>
<kwd lng="en"><![CDATA[autoantibodies]]></kwd>
<kwd lng="en"><![CDATA[signs and symptoms]]></kwd>
<kwd lng="en"><![CDATA[serological tests]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Bañuelos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An update on autoantibodies in systemic lupus erythematosus]]></article-title>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2023</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiriakidou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ching]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic Lupus Erythematosus]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2020</year>
<volume>172</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>ITC81-96</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nagafuchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fujio]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus]]></article-title>
<source><![CDATA[Biomolecules]]></source>
<year>2021</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>928</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zucchi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Silvagni]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Elefante]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic lupus erythematosus: one year in review 2023]]></article-title>
<source><![CDATA[Clin Exp Rheumatol]]></source>
<year>2023</year>
<volume>41</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>997-1008</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnaud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chasset]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunopathogenesis of systemic lupus erythematosus: An update]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2024</year>
<volume>23</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>103648</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Accapezzato]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Caccavale]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Paroli]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2023</year>
<volume>24</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>6578</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lupus nephritis: new progress in diagnosis and treatment]]></article-title>
<source><![CDATA[J Autoimmun]]></source>
<year>2022</year>
<volume>132</volume>
<page-range>102871</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aringer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Costenbader]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Daikh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2019</year>
<volume>71</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1400-12</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reátegui-Sokolova]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ugarte-Gil]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of renal damage in systemic lupus erythematous patients]]></article-title>
<source><![CDATA[RMD Open]]></source>
<year>2020</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fanouriakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kostopoulou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of systemic lupus erythematosus: 2023 update]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2024</year>
<volume>83</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-29</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[YB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2019</year>
<volume>39</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1937-44</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dima]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jurcut]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Baicus]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2018</year>
<volume>38</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1169-78</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pisetsky]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolving story of autoantibodies in systemic lupus erythematosus]]></article-title>
<source><![CDATA[J Autoimmun]]></source>
<year>2020</year>
<volume>110</volume>
<page-range>102356</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meroni]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Tsokos]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>199</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crow]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2023</year>
<volume>82</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>999-1014</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Sammaritano]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic Lupus Erythematosus: A Review]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2024</year>
<volume>331</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1480-91</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target]]></article-title>
<source><![CDATA[J Autoimmun]]></source>
<year>2022</year>
<volume>132</volume>
<page-range>102861</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alforaih]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Whittall-Garcia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Touma]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of Lupus Nephritis]]></article-title>
<source><![CDATA[J Appl Lab Med]]></source>
<year>2022</year>
<volume>7</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1450-67</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the Correlation of SLEDAI-2K and SLE-DAS with Health-Related Quality of Life]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2021</year>
<volume>10</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2137</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical manifestations and diagnosis of systemic lupus erythematosus in adults]]></article-title>
<source><![CDATA[UpToDate]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Renée]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Mercado]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínicas e inmunológicas de lupus eritematoso sistémico aplicando los criterios de clasificación de EULAR/ACR 2019]]></article-title>
<source><![CDATA[Med Int Mex]]></source>
<year>2022</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>507-13</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maloney]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[De Ceulaer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and immunological characteristics of 150 systemic lupus erythematosus patients in Jamaica]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2017</year>
<volume>26</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1448-56</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moriano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bellido-Pastrana]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[San Román Gutiérrez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolution of diagnosis and treatment for lupus nephritis in Spain]]></article-title>
<source><![CDATA[Nefrologia (Engl Ed)]]></source>
<year>2023</year>
<volume>43</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>668-75</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heimovski]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Simioni]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Skare]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systemic lupus erythematosus and Raynaud's phenomenon]]></article-title>
<source><![CDATA[An Bras Dermatol]]></source>
<year>2015</year>
<volume>90</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>837-40</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
